Table 1.

Patient demographics and clinical characteristics

Patient no.	Age, yr	Sex	Race	Year IgAN diagnosed	Treatment	Gross hematuria events during disease course	Persistent microscopic hematuria	Proteinuria in 2020, g/d	Proteinuria between SARS-Cov-2 vaccine doses, g/d	Proteinuria 3 weeks after last SARS-CoV-2 vaccine dose, g/d
1	38	F	W	2005	RAASi	At presentation; during 1 episode of gastroenteritis; occasionally after yearly influenza vaccine	Yes	0.63	0.82	1.40
2	38	F	W	2019	Cyc + Pred (6 mo), then RAASi	At presentation only	Yes	0.43	0.59	0.40

Cyc, cyclophosphamide; F, female; IgAN, IgA nephropathy; Pred, prednisone; RAASi, renin-angiotensin-aldosterone system inhibitor; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; W, white.